BUSINESS
Once-Monthly Injectable Abilify Reduces Total Psychiatric Hospitalization Rates following Disease Relapse: Otsuka, Lundbeck
Otsuka Pharmaceutical and H. Lundbeck A/S of Denmark announced on May 22 that the once-monthly injectable treatment Abilify Maintena (aripiprazole) demonstrated a statistically significant reduction in total psychiatric hospitalization rates for schizophrenia patients previously taking oral antipsychotics who were switched…
To read the full story
BUSINESS
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Co-Promotions Dominate in Oncology, Diabetes Alliances: Fuji Keizai
April 24, 2026
- Medii, Pediatric Neurology Society Build System to Support Elevidys Use
April 24, 2026
- Oncolys’ OBP-301 Wins US Fast Track Designation
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





